RxDoctor Payments Data

Ajay Toppur Ramanakumar, MD

Internal Medicine · Stockton, CANPI 1659539153

Payments from drug & device makers

$8,452in general payments, 2019–2025

Across 137 payments — averaging $61.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$1K
  • E.r. Squibb & Sons, L.L.C.$449
  • Pfizer$194
  • Sanofi-aventis U.S. LLC$175
  • Shockwave Medical, Inc$153
  • plus $867 from 18 others

What the payments were for

  • Travel & lodging$3,88846%
  • Food & beverage$4,56554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,452 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,597,815
Medicare patients
1,921
Services billed
14,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban715$942,330
VyndamaxTafamidis12$270,389
XareltoRivaroxaban213$250,807
EntrestoSacubitril/Valsartan111$162,937
JardianceEmpagliflozin138$157,644
Repatha SureclickEvolocumab121$125,116
MultaqDronedarone Hcl28$47,417
FarxigaDapagliflozin Propanediol38$37,994
Ezetimibe684$26,169
Metoprolol Succinate1,075$17,710
Rosuvastatin Calcium703$15,836
Atorvastatin Calcium1,249$14,371
Praluent PenAlirocumab11$12,752
Ranolazine ErRanolazine85$10,370
VascepaIcosapent Ethyl23$9,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$194$1,212,718727 claims
Johnson & JohnsonXarelto$15$250,807213 claims
NovartisEntresto$24$162,937111 claims
Boehringer IngelheimJardiance$28$157,644138 claims
Sanofi-aventis U.S. LLCMultaq$175$47,41728 claims
AstraZenecaFarxiga$146$37,99438 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$16$11,41323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →